← Leaderboards
Francesca Garretti
Icahn School Of Medicine At Mount Sinai
$224,404
Attributed
$224,404
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $81K · FY2023–25$100K$75K$50K$25K$0
'23
'24
'25
Funding mix
By agency
NIH$224,404 · 1
By mechanism
F32$224,404 · 1
Top collaborators
No co-investigators on record.
Most similar at Icahn School Of Medicine At Mount Sinai
Same institution · by research overlap
- Juan P Wisnivesky$34,328,417
- Keith Magnus Sigel$6,937,762
- Emma Katherine Tara Benn$13,981,090
- Abraham Reichenberg$11,905,270
- Eva Velthorst$1,337,197
Others in their field
Other Rising Stars on “Alzheimer&Apos”
- Kjetil Bjornevik · Harvard University D/B/A Harvard School Of Public Health$3,280,861
- Yanling Wang · Rush University Medical Center$2,986,919
- William G Mantyh · University Of Minnesota$2,961,521
- Allison Mercedes Caban-Holt · University Of Miami School Of Medicine$2,611,182
- Brian Stephen Appleby · Cleveland Clinic Lerner Com-Cwru$2,482,260
- Noah Ray Johnson · University Of Colorado Denver$2,282,487
Research focus
Alzheimer&AposAge YearsCholesterolBiological Adaptation To StressAmino Acid SubstitutionAmyloid DepositionApolipoprotein EBacteriaCrispr/Cas TechnologyBrainCareerCell PhysiologyCellsCellular StressAllelesCognitiveCollaborative EnvironmentComplexAffectCritical ThinkingCytokineDepositionDisorder RiskActivating Transcription Factor 4
Grant awards (3)
Investigating the role of an EIF2B3 variant as an Alzheimer's disease risk modifier$81,040
F32 · FY2025 · AG · contact PI
Investigating the role of an EIF2B3 variant as an Alzheimer's disease risk modifier$74,284
F32 · FY2024 · AG · contact PI
Investigating the role of an EIF2B3 variant as an Alzheimer's disease risk modifier$69,080
F32 · FY2023 · AG · contact PI